Gant61, in particular, has been widely embraced as a pharmacologic tool in numerous proof of principle studies, illustrating the benefits of direct Gli1 inhibition in a number of oncologic indications, including solid (pancreatic, ovarian, prostate, breast, lung, and brain cancer) and liquid tumors (multiple myeloma and acute myeloid leukemia) [33]. Here, GLI1 is linked to acute myeloid leukemia.